PRISM Trial
Phase 1
45
about 4.8 years
18+
1 site in TX
What this study is about
This trial is testing personalized radiotherapy strategies for patients with brain metastases, small cell lung cancer, or solid tumors. The treatment involves a type of radiation therapy called PULSAR, which adapts to each patient's individual response. It aims to determine if this approach is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
- 2.Receive Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: COHORT B-assesses ability to de-escalate dose in good responders by imaging using rule-based imaging-response guided omission of 2nd pulse of PULSAR fractionated SRS (fSRS) for brain metastases
radiation
Oncology